{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:09:29Z","timestamp":1788480569641,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5DP1AI158125"],"award-info":[{"award-number":["5DP1AI158125"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006352","name":"Virginia and D.K. Ludwig Fund for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006352","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chan Zuckerberg Biohub"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-60035-6","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T04:35:26Z","timestamp":1747542926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5584-5073","authenticated-orcid":false,"given":"Soohyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caelan E.","family":"Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0483-8719","authenticated-orcid":false,"given":"Duo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8330-0053","authenticated-orcid":false,"given":"Jianing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic M.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie A.","family":"Travisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V.","family":"Filsinger Interrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora U. J.","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2336-7599","authenticated-orcid":false,"given":"Valerie","family":"Rezek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailey","family":"Wilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Palomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6182-6082","authenticated-orcid":false,"given":"Scott G.","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-3408","authenticated-orcid":false,"given":"Jesse D.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6503-4541","authenticated-orcid":false,"given":"Peter S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,18]]},"reference":[{"key":"60035_CR1","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.4049\/jimmunol.146.8.2578","volume":"146","author":"GM Orloff","year":"1991","unstructured":"Orloff, G. M., Orloff, S. L., Kennedy, M. S., Maddon, P. J. & McDougal, J. S. Penetration of CD4 T cells by HIV-1. The CD4 receptor does not internalize with HIV, and CD4-related signal transduction events are not required for entry. J. Immunol. 146, 2578\u20132587 (1991).","journal-title":"J. Immunol."},{"key":"60035_CR2","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S0952-7915(97)80110-0","volume":"9","author":"JP Moore","year":"1997","unstructured":"Moore, J. P., Trkola, A. & Dragic, T. Co-receptors for HIV-1 entry. Curr. Opin. Immunol. 9, 551\u2013562 (1997).","journal-title":"Curr. Opin. Immunol."},{"key":"60035_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0092-8674(00)81430-0","volume":"93","author":"DC Chan","year":"1998","unstructured":"Chan, D. C. & Kim, P. S. HIV entry and its inhibition. Cell 93, 681\u2013684 (1998).","journal-title":"Cell"},{"key":"60035_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1146\/annurev.biochem.70.1.777","volume":"70","author":"DM Eckert","year":"2001","unstructured":"Eckert, D. M. & Kim, P. S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777\u2013810 (2001).","journal-title":"Annu. Rev. Biochem."},{"key":"60035_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/nsmb.1456","volume":"15","author":"SC Harrison","year":"2008","unstructured":"Harrison, S. C. Viral membrane fusion. Nat. Struct. Mol. Biol. 15, 690\u2013698 (2008).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"60035_CR6","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.58411","volume":"9","author":"MS Ladinsky","year":"2020","unstructured":"Ladinsky, M. S. et al. Electron tomography visualization of HIV-1 fusion with target cells using fusion inhibitors to trap the pre-hairpin intermediate. eLife 9, e58411 (2020).","journal-title":"eLife"},{"key":"60035_CR7","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/3293","volume":"4","author":"JM Kilby","year":"1998","unstructured":"Kilby, J. M. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4, 1302\u20131307 (1998).","journal-title":"Nat. Med."},{"key":"60035_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrd1091","volume":"2","author":"J LaBonte","year":"2003","unstructured":"LaBonte, J., Lebbos, J. & Kirkpatrick, P. Enfuvirtide. Nat. Rev. Drug Discov. 2, 345\u2013346 (2003).","journal-title":"Nat. Rev. Drug Discov."},{"key":"60035_CR9","doi-asserted-by":"publisher","first-page":"14759","DOI":"10.1073\/pnas.0506927102","volume":"102","author":"MD Miller","year":"2005","unstructured":"Miller, M. D. et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc. Natl Acad. Sci. Usa. 102, 14759\u201314764 (2005).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"60035_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","volume":"89","author":"DC Chan","year":"1997","unstructured":"Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263\u2013273 (1997).","journal-title":"Cell"},{"key":"60035_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4161\/rna.9.1.18178","volume":"9","author":"J Fernandes","year":"2012","unstructured":"Fernandes, J., Jayaraman, B. & Frankel, A. The HIV-1 Rev response element: an RNA scaffold that directs the cooperative assembly of a homo-oligomeric ribonucleoprotein complex. RNA Biol. 9, 6\u201311 (2012).","journal-title":"RNA Biol."},{"key":"60035_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.103062","volume":"299","author":"TUJ Bruun","year":"2023","unstructured":"Bruun, T. U. J. et al. Structure-guided stabilization improves the ability of the HIV-1 gp41 hydrophobic pocket to elicit neutralizing antibodies. J. Biol. Chem. 299, 103062 (2023).","journal-title":"J. Biol. Chem."},{"key":"60035_CR13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nsmb1127","volume":"13","author":"MA Luftig","year":"2006","unstructured":"Luftig, M. A. et al. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate\u2013directed antibody. Nat. Struct. Mol. Biol. 13, 740\u2013747 (2006).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"60035_CR14","doi-asserted-by":"publisher","first-page":"e1001182","DOI":"10.1371\/journal.ppat.1001182","volume":"6","author":"E Gustchina","year":"2010","unstructured":"Gustchina, E. et al. Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41. PLoS Pathog. 6, e1001182 (2010).","journal-title":"PLoS Pathog."},{"key":"60035_CR15","doi-asserted-by":"publisher","first-page":"e1001195","DOI":"10.1371\/journal.ppat.1001195","volume":"6","author":"C Sabin","year":"2010","unstructured":"Sabin, C. et al. Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. PLoS Pathog. 6, e1001195 (2010).","journal-title":"PLoS Pathog."},{"key":"60035_CR16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2018027118","volume":"118","author":"DC Montefiori","year":"2021","unstructured":"Montefiori, D. C. et al. The high-affinity immunoglobulin receptor Fc\u03b3RI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat. Proc. Natl. Acad. Sci. USA 118, e2018027118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60035_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02350-20","volume":"95","author":"AA Rubio","year":"2021","unstructured":"Rubio, A. A. et al. A derivative of the D5 monoclonal antibody that targets the gp41 n-heptad repeat of HIV-1 with broad tier-2-neutralizing activity. J. Virol. 95, e02350-20 (2021).","journal-title":"J. Virol."},{"key":"60035_CR18","doi-asserted-by":"publisher","first-page":"e2215792120","DOI":"10.1073\/pnas.2215792120","volume":"120","author":"BN Bell","year":"2023","unstructured":"Bell, B. N., Bruun, T. U. J., Friedland, N. & Kim, P. S. HIV-1 prehairpin intermediate inhibitors show efficacy independent of neutralization tier. Proc. Natl. Acad. Sci. USA 120, e2215792120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60035_CR19","doi-asserted-by":"publisher","first-page":"4660","DOI":"10.1182\/blood-2007-12-130070","volume":"111","author":"F Groot","year":"2008","unstructured":"Groot, F., Welsch, S. & Sattentau, Q. J. Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood 111, 4660\u20134663 (2008).","journal-title":"Blood"},{"key":"60035_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nm0703-847","volume":"9","author":"M Pope","year":"2003","unstructured":"Pope, M. & Haase, A. T. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat. Med 9, 847\u2013852 (2003).","journal-title":"Nat. Med"},{"key":"60035_CR21","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1128\/JVI.02108-09","volume":"84","author":"MS Seaman","year":"2010","unstructured":"Seaman, M. S. et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439\u20131452 (2010).","journal-title":"J. Virol."},{"key":"60035_CR22","doi-asserted-by":"publisher","first-page":"13540","DOI":"10.1073\/pnas.1304985110","volume":"110","author":"CS Pace","year":"2013","unstructured":"Pace, C. S. et al. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc. Natl. Acad. Sci. USA 110, 13540\u201313545 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60035_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/QAI.0000000000000218","volume":"66","author":"M Sun","year":"2014","unstructured":"Sun, M. et al. Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. JAIDS J. Acquired Immune Defic. Syndromes 66, 473\u2013483 (2014).","journal-title":"JAIDS J. Acquired Immune Defic. Syndromes"},{"key":"60035_CR24","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.cell.2016.05.024","volume":"165","author":"Y Huang","year":"2016","unstructured":"Huang, Y. et al. Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity. Cell 165, 1621\u20131631 (2016).","journal-title":"Cell"},{"key":"60035_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-019-0493-y","volume":"16","author":"T Moshoette","year":"2019","unstructured":"Moshoette, T., Ali, S. A., Papathanasopoulos, M. A. & Killick, M. A. Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1. Retrovirology 16, 31 (2019).","journal-title":"Retrovirology"},{"key":"60035_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12985-022-01876-1","volume":"19","author":"T Moshoette","year":"2022","unstructured":"Moshoette, T., Papathanasopoulos, M. A. & Killick, M. A. HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6. Virol. J. 19, 143 (2022).","journal-title":"Virol. J."},{"key":"60035_CR27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1128\/AAC.00942-08","volume":"53","author":"JM Jacobson","year":"2009","unstructured":"Jacobson, J. M. et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob. Agents Chemother. 53, 450\u2013457 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"60035_CR28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.4161\/mabs.21379","volume":"4","author":"C Klein","year":"2012","unstructured":"Klein, C. et al. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. mAbs 4, 653\u2013663 (2012).","journal-title":"mAbs"},{"key":"60035_CR29","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1080\/19420862.2016.1160192","volume":"8","author":"AD Tustian","year":"2016","unstructured":"Tustian, A. D., Endicott, C., Adams, B., Mattila, J. & Bak, H. Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity. mAbs 8, 828\u2013838 (2016).","journal-title":"mAbs"},{"key":"60035_CR30","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1128\/JVI.72.4.2855-2864.1998","volume":"72","author":"EJ Platt","year":"1998","unstructured":"Platt, E. J., Wehrly, K., Kuhmann, S. E., Chesebro, B. & Kabat, D. Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1. J. Virol. 72, 2855\u20132864 (1998).","journal-title":"J. Virol."},{"key":"60035_CR31","doi-asserted-by":"crossref","unstructured":"Montefiori, D. C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. CP in Immunology 64, (2004).","DOI":"10.1002\/0471142735.im1211s64"},{"key":"60035_CR32","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1128\/JVI.02853-13","volume":"88","author":"A deCamp","year":"2014","unstructured":"deCamp, A. et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 88, 2489\u20132507 (2014).","journal-title":"J. Virol."},{"key":"60035_CR33","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1073\/pnas.0802203105","volume":"105","author":"BF Keele","year":"2008","unstructured":"Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. Usa. 105, 7552\u20137557 (2008).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"60035_CR34","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.1073\/pnas.1304288110","volume":"110","author":"NF Parrish","year":"2013","unstructured":"Parrish, N. F. et al. Phenotypic properties of transmitted founder HIV-1. Proc. Natl. Acad. Sci. USA 110, 6626\u20136633 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60035_CR35","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med 384, 1003\u20131014 (2021).","journal-title":"N. Engl. J. Med"},{"key":"60035_CR36","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nature13808","volume":"514","author":"M Pancera","year":"2014","unstructured":"Pancera, M. et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514, 455\u2013461 (2014).","journal-title":"Nature"},{"key":"60035_CR37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/COH.0000000000000360","volume":"12","author":"M Pancera","year":"2017","unstructured":"Pancera, M., Changela, A. & Kwong, P. D. How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. Curr. Opin. HIV AIDS 12, 229\u2013240 (2017).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"60035_CR38","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1084\/jem.185.4.621","volume":"185","author":"RI Connor","year":"1997","unstructured":"Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S. & Landau, N. R. Change in coreceptor use correlates with disease progression in HIV-1\u2013infected individuals. J. Exp. Med. 185, 621\u2013628 (1997).","journal-title":"J. Exp. Med."},{"key":"60035_CR39","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.chom.2023.05.025","volume":"31","author":"CE Radford","year":"2023","unstructured":"Radford, C. E. et al. Mapping the neutralizing specificity of human anti-HIV serum by deep mutational scanning. Cell Host Microbe 31, 1200\u20131215.e9 (2023).","journal-title":"Cell Host Microbe"},{"key":"60035_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cell.2016.05.055","volume":"166","author":"CA Simonich","year":"2016","unstructured":"Simonich, C. A. et al. HIV-1 neutralizing antibodies with limited hypermutation from an infant. Cell 166, 77\u201387 (2016).","journal-title":"Cell"},{"key":"60035_CR41","unstructured":"Wensing, A. M. et al. 2017 update of the drug resistance mutations in HIV-1.Top Antivir. Med. 24, 132\u2013133 (2017)."},{"key":"60035_CR42","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/v11050439","volume":"11","author":"AS Dingens","year":"2019","unstructured":"Dingens, A. S., Arenz, D., Overbaugh, J. & Bloom, J. D. Massively parallel profiling of HIV-1 resistance to the fusion inhibitor enfuvirtide. Viruses 11, 439 (2019).","journal-title":"Viruses"},{"key":"60035_CR43","doi-asserted-by":"publisher","first-page":"e1002649","DOI":"10.1371\/journal.ppat.1002649","volume":"8","author":"SG Kitchen","year":"2012","unstructured":"Kitchen, S. G. et al. In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog. 8, e1002649 (2012).","journal-title":"PLoS Pathog."},{"key":"60035_CR44","doi-asserted-by":"publisher","first-page":"7397","DOI":"10.1128\/JVI.00656-09","volume":"83","author":"LG Perez","year":"2009","unstructured":"Perez, L. G., Costa, M. R., Todd, C. A., Haynes, B. F. & Montefiori, D. C. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. J. Virol. 83, 7397\u20137410 (2009).","journal-title":"J. Virol."},{"key":"60035_CR45","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1128\/JVI.00278-13","volume":"87","author":"LG Perez","year":"2013","unstructured":"Perez, L. G., Zolla-Pazner, S. & Montefiori, D. C. Antibody-dependent, Fc\u03b3RI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis. J. Virol. 87, 5287\u20135290 (2013).","journal-title":"J. Virol."},{"key":"60035_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02249-17","volume":"92","author":"E Rujas","year":"2018","unstructured":"Rujas, E. et al. Functional optimization of broadly neutralizing HIV-1 antibody 10E8 by promotion of membrane interactions. J. Virol. 92, e02249-17 (2018).","journal-title":"J. Virol."},{"key":"60035_CR47","doi-asserted-by":"publisher","first-page":"e1006212","DOI":"10.1371\/journal.ppat.1006212","volume":"13","author":"A Irimia","year":"2017","unstructured":"Irimia, A. et al. Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design. PLoS Pathog. 13, e1006212 (2017).","journal-title":"PLoS Pathog."},{"key":"60035_CR48","doi-asserted-by":"publisher","first-page":"e01647","DOI":"10.1128\/jvi.01647-22","volume":"97","author":"S Kim","year":"2023","unstructured":"Kim, S., Filsinger Interrante, M. V. & Kim, P. S. Enhancing HIV-1 neutralization by increasing the local concentration of membrane-proximal external region-directed broadly neutralizing antibodies. J. Virol. 97, e01647\u201322 (2023).","journal-title":"J. Virol."},{"key":"60035_CR49","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.virol.2008.04.005","volume":"377","author":"JD Nelson","year":"2008","unstructured":"Nelson, J. D. et al. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 377, 170\u2013183 (2008).","journal-title":"Virology"},{"key":"60035_CR50","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1126\/science.aad2450","volume":"351","author":"JH Lee","year":"2016","unstructured":"Lee, J. H., Ozorowski, G. & Ward, A. B. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351, 1043\u20131048 (2016).","journal-title":"Science"},{"key":"60035_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07962-9","volume":"10","author":"P Carravilla","year":"2019","unstructured":"Carravilla, P. et al. Molecular recognition of the native HIV-1 MPER revealed by STED microscopy of single virions. Nat. Commun. 10, 78 (2019).","journal-title":"Nat. Commun."},{"key":"60035_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34008-y","volume":"13","author":"S Yang","year":"2022","unstructured":"Yang, S. et al. Dynamic HIV-1 spike motion creates vulnerability for its membrane-bound tripod to antibody attack. Nat. Commun. 13, 6393 (2022).","journal-title":"Nat. Commun."},{"key":"60035_CR53","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479\u2013484 (2018).","journal-title":"Nature"},{"key":"60035_CR54","doi-asserted-by":"publisher","first-page":"e653","DOI":"10.1016\/S2352-3018(23)00140-6","volume":"10","author":"ME Sobieszczyk","year":"2023","unstructured":"Sobieszczyk, M. E. et al. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial. Lancet HIV 10, e653\u2013e662 (2023).","journal-title":"Lancet HIV"},{"key":"60035_CR55","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.34420","volume":"7","author":"HK Haddox","year":"2018","unstructured":"Haddox, H. K., Dingens, A. S., Hilton, S. K., Overbaugh, J. & Bloom, J. D. Mapping mutational effects along the evolutionary landscape of HIV envelope. eLife 7, e34420 (2018).","journal-title":"eLife"},{"key":"60035_CR56","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/s41589-022-01140-1","volume":"18","author":"PA-B Weidenbacher","year":"2022","unstructured":"Weidenbacher, P. A.-B. et al. Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors. Nat. Chem. Biol. 18, 1270\u20131276 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"60035_CR57","doi-asserted-by":"publisher","first-page":"9002","DOI":"10.1128\/JVI.00423-09","volume":"83","author":"NM Provine","year":"2009","unstructured":"Provine, N. M., Puryear, W. B., Wu, X., Overbaugh, J. & Haigwood, N. L. The infectious molecular clone and pseudotyped virus models of human immunodeficiency virus type 1 exhibit significant differences in virion composition with only moderate differences in infectivity and inhibition sensitivity. J. Virol. 83, 9002\u20139007 (2009).","journal-title":"J. Virol."},{"key":"60035_CR58","doi-asserted-by":"crossref","unstructured":"Montefiori, D. C. Measuring HIV Neutralization in a Luciferase Reporter Gene Assay. in HIV Protocols (eds. Prasad, V. R. & Kalpana, G. V.) vol. 485 395\u2013405 (Humana Press, 2009).","DOI":"10.1007\/978-1-59745-170-3_26"},{"key":"60035_CR59","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","unstructured":"Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131\u2013146 (2014).","journal-title":"J. Immunol. Methods"},{"key":"60035_CR60","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cell.2023.02.001","volume":"186","author":"B Dadonaite","year":"2023","unstructured":"Dadonaite, B. et al. A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike. Cell 186, 1263\u20131278.e20 (2023).","journal-title":"Cell"},{"key":"60035_CR61","doi-asserted-by":"publisher","DOI":"10.1093\/ve\/veac110","volume":"8","author":"TC Yu","year":"2022","unstructured":"Yu, T. C. et al. A biophysical model of viral escape from polyclonal antibodies. Virus Evolut. 8, veac110 (2022).","journal-title":"Virus Evolut."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60035-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60035-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60035-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T06:02:51Z","timestamp":1747548171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60035-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,18]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60035"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60035-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,18]]},"assertion":[{"value":"28 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4617"}}